|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification
No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
The
|
MOLECULIN BIOTECH, INC.
|
|||
Date: November 3, 2023
|
|||
By:
|
/s/ Jonathan P. Foster
|
||
Jonathan P. Foster
|
|||
Chief Financial Officer
|
Document And Entity Information |
Nov. 02, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | MOLECULIN BIOTECH, INC. |
Document, Type | 8-K |
Document, Period End Date | Nov. 02, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-37758 |
Entity, Tax Identification Number | 47-4671997 |
Entity, Address, Address Line One | 5300 Memorial Drive, Suite 950 |
Entity, Address, City or Town | Houston |
Entity, Address, State or Province | TX |
Entity, Address, Postal Zip Code | 77007 |
City Area Code | 713 |
Local Phone Number | 300-5160 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity, Emerging Growth Company | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | MBRX |
Security Exchange Name | NASDAQ |
Amendment Flag | false |
Entity, Central Index Key | 0001659617 |
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end
!6>V ;4&8%+]5509[&D/O7P]_51%:*2-N5O=^A/5W[;
MGUH;L#V;]\G9-STNVC1L(WQ-ZL;[URXC4VW3:70SY;N,G!#(I71B?TO9\M&)
M%S1=MLW6BB_+D!; 9?"U]I2*Z$VMH0U;C7R$K7,DW;N(3VB@Q1=7.IHV=NTY
M_9X^MCA/F-3,/T.6225?\BLA^G&XN[1"HK;0V]>ZJ1IC6?/IWS.0GU/O:5
MC21')#_NB6NIPF7(I MZ0GY]D5JI[B'O/8=*T1I"O25Z*O*SDT;1L.8+$L\R
M^W1$+$Y^KW2>2IL="93I<>VK7IPS*-%TN-#?.F!Q?KC%)KR\$IM,C4_($"R,
M08^E_\-R?: 4ST[U'GC#;YEH/?-MN/F.4_HQ+NPLK?G,JGH6X4>V'5K+7$2;
M'7[U["G3?&6.15'[F<9N<\T)]?7